<DOC>
	<DOCNO>NCT02228239</DOCNO>
	<brief_summary>The purpose study evaluate effect esketamine compare placebo drive performance assess mean difference standard deviation lateral position ( SDLP ) on-road drive test healthy participant .</brief_summary>
	<brief_title>Study Assess Effects Esketamine Safety On-road Driving Healthy Participants</brief_title>
	<detailed_description>This Phase 1 , randomize ( study medication assign participant chance ) , double-blind ( neither Investigator participant know treatment participant receives ) , placebo-controlled ( placebo inactive substance compare drug test whether drug real effect clinical trial ) , single-center , single-dose 3-way crossover ( medication provide participant different sequence ) study esketamine healthy participant . Participants randomly assign 1 6 treatment sequence . The study consist 3 part : Screening Phase ( 21 day 1 day prior first dose administration ) , 3-way crossover double-blind , single dose treatment Phase ( 45 day ) follow-up Phase ( 7 10 day last dose administration ) . The maximum study duration participant exceed 7 week . Participants receive either Treatment A ( esketamine 84 milligram ( mg ) intranasal 1 placebo capsule ) , Treatment B ( placebo intranasal 1 mirtazapine 30 mg capsule ) Treatment C ( placebo intranasal placebo capsule ) treatment period . Driving performance assess primarily mean difference SDLP road drive test . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>Body mass index ( BMI ) ( weight [ kg ] /height^2 [ m^2 ] ) 18 30 kg/m^2 ( inclusive ) , body weight less 45 kg Blood pressure ( participant supine 5 minute ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic Screening predose Day 1 Period 1 A woman childbearing potential must negative urine pregnancy test Screening predose Day 1 Period 1 A 12lead electrocardiogram ( ECG ) consistent normal cardiac conduction function Screening predose Day 1 Period 1 , include : sinus rhythm , heart rate 45 90 beat per minute ( bpm ) , QTc interval less equal 450 millisecond ( m ) , QRS interval le 120 m , PR interval le 200 m morphology consistent healthy cardiac conduction function 1st degree AV block exclusionary Participant valid driving license 3 year , driven least 5000 kilometer ( km ) past year driving car regularly Participant clinically significant liver renal insufficiency ; cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic ( include cataplexy cognitive impairment ) , hematologic , rheumatologic , psychiatric , metabolic disturbance . A significant primary sleep disorder exclusionary Clinically significant abnormal value hematology , clinical chemistry , urinalysis Screening , deem appropriate Investigator Clinically significant abnormal physical examination , vital sign , 12lead electrocardiogram ( ECG ) Screening Day 1 Period 1 , deem appropriate Investigator Anatomical medical condition may impede delivery absorption study medication ( example , undergone facial reconstruction , rhinoplasty , significant structural functional abnormality nose upper airway ; obstruction mucosal lesion nostril nasal passage ; undergone sinus surgery previous 2 year ; sign symptom rhinitis predose Day 1 Period 1 ) Has abnormal deviate nasal septum one follow symptom : blockage one nostril , nasal congestion ( especially 1sided ) , frequent nosebleed , frequent sinus infection , time facial pain , headache , postnasal drip</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Esketamine</keyword>
	<keyword>Mirtazapine</keyword>
	<keyword>Psychomotor .</keyword>
</DOC>